2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

3514 A phase 1b trial of the EZH2 inhibitor tazemetostat combined with CAR T cell therapy in B cell lymphomas shows no short-term expansion of clonal hematopoiesis

Caitlin Gribbin, MD, Yamil Mahmoud, PhD2, Ioannis Karagiannidis, PhD3, Yusuke Isshiki, MD PhD4, Sujae Lee5, Jizhi Yan6, Christopher Hackett, MD PhD7, Selina Chen-Kiang, PhD8, John Leonard, MD9, Ari Melnick, MD10, Richard R Furman, MD11, Juliet Barker, MB, BS12, Giorgio Inghirami, MD13, Peter Martin, FRCPC, MD, MS14, Wendy Beguelin, PhD15, Samuel Yamshon, MD16
1 Weill Cornell Medicine, New York, New York, United States
2 NYU Grossman School of Medicine, New York, New York, United States
3 NYU Grossman School of Medicine, New York, New York, United States, Weill Cornell Medicine, New York, New York, United States
4 Weill Cornell Medicine, New York, New York, United States
5 NYU Grossman School of Medicine, New York, New York, United States, Weill Cornell Medicine, New York, New York, United States
6 NYU Grossman School of Medicine, New York, New York, United States, Weill Cornell Medicine, New York, New York, United States
7 Weill Cornell Medicine, New York, New York, United States
8 Weill Cornell Medicine, New York, New York, United States
9 NYU Grossman School of Medicine, New York, New York, United States, Weill Cornell Medicine, New York, New York, United States
10 Josep Carreras Leukaemia Research Institute, Barcelona, Spain, Weill Cornell Medicine, New York, New York, United States
11 Weill Cornell Medicine, New York, New York, United States
12 Weill Cornell Medicine, New York, New York, United States
13 Weill Cornell Medicine, New York, New York, United States
14 NYU Grossman School of Medicine, New York, New York, United States, Weill Cornell Medicine, New York, New York, United States
15 NYU Grossman School of Medicine, New York, New York, United States, Weill Cornell Medicine, New York, New York, United States
16 NYU Grossman School of Medicine, New York, New York, United States, Weill Cornell Medicine, New York, New York, United States

Background: Most lymphoma patients relapse after chimeric antigen receptor (CAR) T cell therapy through B cell and T cell-mediated resistance mechanisms. Preclinical studies demonstrated that EZH2 inhibition enhances T cell-mediated lymphoma killing by promoting a less exhausted, memory-like T cell state while sensitizing lymphoma cells to T cell therapies. We evaluated the use of EZH2 inhibitor tazemetostat (taz) and CAR T cell therapy in R/R B cell lymphoma. In March 2026, Ipsen initiated global withdrawal of taz after hematologic second primary malignancies were observed in SYMPHONY-1, a phase III trial investigating taz/lenalidomide/rituximab in R/R follicular lymphoma. Given that clonal hematopoiesis (CH) can precede myeloid neoplasia, we retrospectively assessed myeloid-associated variants in trial participants to delineate a potential association between taz and CH dynamics.

Methods: This phase Ib trial enrolled patients with R/R diffuse large B cell, follicular, or mantle cell lymphoma (DLBCL, FL, MCL) receiving standard-of-care CAR T cell therapy. Taz 800mg twice daily was dosed for ≥7 days before leukapheresis and continued until lymphodepletion (LD), then resumed after count recovery for up to 6 months in patients with complete response (CR) and 12 months in those with partial response (PR). Primary endpoints included feasibility and safety; secondary endpoints included response, survival, and effects on T cells as well as on minimal residual disease (MRD). To quantify MRD and CH burden on circulating DNA, CAncer Personalized Profiling by deep Sequencing (CAPP-seq) was performed on plasma collected before taz initiation, before LD, and at the latest post-CAR T timepoint. Median unique on-target coverage was 848x. Variants were called tumor-only (Mutect2 with gnomAD germline filtering and VarDict) and force-genotyped by pileup at every timepoint.

Results: 13 patients were treated including 7 DLBCL, 5 FL, and 1 MCL. Median age was 68 (range, 41-84) and median prior lines of therapy was 2 (range, 1-4). All patients completed CAR T infusion; toxicities were consistent with those expected with CAR T cell therapy. CRS and ICANS occurred in 10 (77%) and 6 (46%) patients; grade ≥3 neutropenia and anemia after day 30 occurred in 10 (77%) and 2 (15%) patients. Overall and CR rates were 100% and 77%. No patient developed MDS or AML. At a median follow-up of 18 mo, 54% remained progression-free and 77% alive. AEs are detailed in Blood (2025) 146 (Supp 1): 1011.

The MCL patient was excluded from CH analysis. Among 12 evaluable patients, 34 samples were analyzed; 12/12 (100%), 11/12 (92%), and 11/12 (92%) had samples before taz, before LD, and after CAR T infusion. The latest timepoint occurred at a mean 90 days (range 30-180) after CAR T. Tumor-only calling with germline/population filtering identified 73 high-confidence somatic reporter variants, predominantly involving B cell lymphoma-associated genes (including MYC, BCL2, BCL6, GNA13, TNFRSF14, and TP53). Of 8 patients with a detectable baseline clone, ctDNA cleared in 5 and remained detectable in 3; 4 were non-evaluable due to low tumor burden, which tracked with lower cfDNA input (rho=0.62, p=0.03). At the time of MRD assessment, 3 patients with detectable ctDNA were in CR while 4 of 5 ctDNA undetectable patients were in CR. CH was assessed using canonical myeloid genes (DNMT3A, TET2, ASXL1, PPM1D, TP53, ATM, CHEK2, CBL, IDH1, SF3B1, U2AF1; DTA and DNA-damage-response classes), calling variants at VAF ≥2% (hotspots ≥1%), excluding immunoglobulin/HLA and recurrent artifact loci, and force-genotyping each across all timepoints; TP53 was arbitrated per patient as tumor vs CHIP by VAF. After stringent filtering (two-caller support or canonical hotspot, excluding sequencing-artifact substitutions), high-confidence CH was detected in 5/12 patients (42%; 9 variants, median 2 per carrier). The most frequently mutated CH genes were TET2 (3 variants, 33%), TP53 (2, 22%), and DNMT3A, ASXL1, CHEK2, and CBL (1 each). 6 CH clones (TET2, TP53, DNMT3A, and CBL) declined and 3 were stable (TET2, ASXL1, and CHEK2). No CH clones expanded and CH dynamics were discordant with MRD and response.

Conclusion: In this small cohort, taz plus CAR T was feasible with expected CAR T toxicities. cfDNA profiling did not identify a pattern of emerging or expanding myeloid-associated clones in early follow-up. Additional analyses of transcriptional and inflammatory changes will be presented at ASH.

Yamil Mahmoud, PhD: No relevant conflicts of interest to declare.